Anticoagulation during Cardiopulmonary bypass in Patients with Heparin-Induced Thrombocytopenia using Heparin and the Platelet Glycoprotein IIb-IIIa Antagonist

Nandate K

doi:10.16966/2470-9956.109

Abstract

Anticoagulation during Cardiopulmonary bypass in Patients with Heparin-Induced Thrombocytopenia using Heparin and the Platelet Glycoprotein IIb-IIIa Antagonist

Highlights

Heparin induced thrombocytopenia (HIT) is a potentially devastating prothrombotic disease associated with heparin therapy usually occurring after five days or more of therapy [1]
The surgery should be delayed up to 6 months after the occurrence of HIT to allow the antibodies for heparin to disappear [2]
We chose tirofiban plus heparin due to the superiority of monitoring the anticoagulant effect, the potential of less bleeding with the reversal of heparin, and relatively shorter half life of tirofiban effects [4,5]

Summary

Open Access

Koichiro Nandate* Department of Anesthesiology, Harborview Medical Center, University of Washington, USA Received date: 31 Mar 2016; Accepted date: 18 Apr 2016; Published date: 22 Apr 2016. Citation: Nandate K (2016) Anticoagulation during Cardiopulmonary bypass in Patients with HeparinInduced Thrombocytopenia using Heparin and the Platelet Glycoprotein IIb-IIIa Antagonist. J Clin Anesth Manag 1(3): doi http://dx.doi.org/10.16966/24709956.109

Introduction

Findings

Discussion